Sydney M Crago

1 week ago | optometrytimes.com | Sydney M Crago |Modern Retina |Emily Kaiser Maharjan

The FDA has granted 510(k) clearance to BVI Medical for its glaucoma surgical system, called Leos (Laser Endoscopy Ophthalmic System). Leos is designed to introduce a novel, intuitive Laser ECP procedure that can integrate seamlessly into the surgical workflow. Notably this is the only laser system that lowers intraocular pressure by addressing aqueous humor production in a minimally invasive ab interno procedure.

1 week ago | modernretina.com | Sydney M Crago

April 17, 2025Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida. Retina World Congress 2025 will take place May 8-11. As researchers prepare for their, presentation, we are highlighting the upcoming sessions that are scheduled for this meeting, which will be held in Fort Lauderdale, Florida. Note: The following list of presentations are in alphabetical order by company.

1 week ago | modernretina.com | Sydney M Crago

April 16, 2025A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025. Regeneron has proposed a longer dosing duration for the high-dose (HD) formulation of aflibercept (EYLEA HD).

1 week ago | ophthalmologytimes.com | Sydney M Crago

Regeneron has proposed a longer dosing duration for the high-dose (HD) formulation of aflibercept (EYLEA HD).

1 week ago | optometrytimes.com | Sydney M Crago |Modern Retina

Oculis Holdings has completed enrollment in both Phase 3 DIAMOND-1 (NCT05066997) and DIAMOND-2 (NCT06172257) trials. These trials are investigating the company’s OCS-01 eye drops for the treatment of diabetic macular degeneration (DME) and are designed as pivotal registration studies to support global marketing applications including NDA submission and approval by the US Food and Drug Administration (FDA).